A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU)

Trial Profile

A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Acronyms CUTEX
  • Most Recent Events

    • 04 Apr 2017 According to the results published in the Journal of Allergy and Clinical Immunology, status changed from active, no longer recruiting to discontinued, as the study met its primary endpoint at the planned interim analysis
    • 04 Apr 2017 Primary endpoint (Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo) has been met, according to the results published in the Journal of Allergy and Clinical Immunology
    • 04 Apr 2017 Results published in the Journal of Allergy and Clinical Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top